1 226

Cited 18 times in

Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction.

Authors
 Hyun Kuk Kim  ;  Myung Ho Jeong  ;  Young Keun Ahn  ;  Jong Hyun Kim  ;  Shung Chull Chae  ;  Young Jo Kim  ;  Seung Ho Hur  ;  In Whan Seong  ;  Taek Jong Hong  ;  Dong Hoon Choi  ;  Myeong Chan Cho  ;  Chong Jin Kim  ;  Ki Bae Seung  ;  Wook Sung Chung  ;  Yang Soo Jang  ;  Seung Woon Rha  ;  Jang Ho Bae  ;  Jeong Gwan Cho  ;  Seung Jung Park 
Citation
 AMERICAN JOURNAL OF CARDIOLOGY, Vol.105(6) : 813-818, 2010 
Journal Title
 AMERICAN JOURNAL OF CARDIOLOGY 
ISSN
 0002-9149 
Issue Date
2010
MeSH
Aged ; Angioplasty, Balloon, Coronary* ; Coronary Angiography ; Coronary Restenosis/diagnostic imaging ; Drug-Eluting Stents*/adverse effects ; Electrocardiography* ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Myocardial Infarction/drug therapy ; Myocardial Infarction/physiopathology ; Myocardial Infarction/therapy* ; Sirolimus/analogs & derivatives* ; Thrombosis/diagnostic imaging
Abstract
Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs.
Full Text
http://www.sciencedirect.com/science/article/pii/S0002914909026794
DOI
10.1016/j.amjcard.2009.11.009
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100963
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links